Review & Perspective

Split Viewer

Public Health Weekly Report 2025; 18(4): 197-221

Published online December 17, 2024

https://doi.org/10.56786/PHWR.2025.18.4.3

© The Korea Disease Control and Prevention Agency

Prospects of Smoking Hazards Research Using Lung Organoid

Ryeo-Eun Go , Kyoungin Na , Su-Min Seong , Ye-Ji Kang , Yong Ae Jeong , Younjhin Ahn *

Division of Climate Change and Health Hazard, Department of Health Hazard Response, Korea Disease Control and Prevention Agency, Cheongju, Korea

*Corresponding author: Younjhin Ahn, Tel: +82-43-219-2950, E-mail: carotene@korea.kr

Received: November 13, 2024; Revised: December 9, 2024; Accepted: December 17, 2024

This is an Open Access aritcle distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted distribution, and reproduction in any medium, provided the original work is properly cited.

Cigarette use is a health hazard that has been reported to reduce life expectancy, increase the risk of death, and result in high socioeconomic costs. New cigarettes increase the ratio of users and reduce the perception of harm to cigarettes by adding liquid nicotine, flavor, and taste. However, aerosols from cigarettes are presumed to be non harmless vapors. Because health effects greatly depend on smokers’ behaviors, the risk of smoking cannot be used to assess the content of harmful chemicals. Accordingly, we conducted an experiment based on behavioral surveys of smokers to evaluate the health effects of exposure to harmful substances. Following this global trend, alternative animal testing methods are proposed to ban animal testing. Therefore, we reviewed the necessity of alternative animal testing for smoking hazards. Organoids are three-dimensional organized cell-derived organs that can be studied in tissues. Therefore, lung organoids can be used as biological tools for smoking hazard research. Six research papers on the current situation of smoking hazard using lung-organoids have been confirmed. These papers discuss the effects of smoking on lung organoids production or pathway study of lung disease by smoking based on the chronic obstructive pulmonary disease. We examined lung organoid-related studies on lung diseases. Eventually, we will apply the results of exposure to harmful substances following smokers’ behaviors from experiments.

Key words Smoking hazard; Cigarette; Electronic nicotine delivery systems; Lung-organoids; Lung disease model

Key messages

① What is known previously?

Previously, experiments on smoking hazards have been conducted using cell and animal models for inhalation exposure. Organoids are known to overcome the limitations of cell-organ interactions and ethical issues in animal experiments.

② What new information is presented?

Lung organoids can reproduce parts of organ, depending on their constituent cells. Disease-specific lung organoids can be generated using chemicals, thereby inducing changes in gene expression and stem cells.

③ What are implications?

The lung organoid model can regenerate complex cellular structures and interactions, thereby mimicking the major diseases caused by smoking, may be used in smoking research.

Smoking and second-hand smoke are major causes of health issues (Table 1). Continued smoking among lung cancer patients results in a poor prognosis, including an increased risk of recurrence and reduced treatment effectiveness. According to the “Comprehensive Report on the Harms of Tobacco” by the Korea Disease Control and Prevention Agency (KDCA), smoking directly causes approximately 58,000 deaths annually, with associated socioeconomic costs amounting to 12 trillion won [1]. Republic of Korea (ROK) has implemented tobacco control measures, including a national smoking cessation policy, which successfully reduced the smoking rate among adult males from 66% in 1998 to 31% in 2021 [2]. However, with the introduction of new tobacco products such as electronic nicotine delivery systems (ENDS) (2008) and heated tobacco products (HTPs) (2017), the behaviors of cigarette users have been changing significantly. ENDS allow users to customize their nicotine levels, scents, and flavors, which enhances their appeal and potential for abuse (dependence). Additionally, sweet flavors and aromas are known to diminish users’ perceptions of tobacco-related harm [3]. According to the “Report on the Harms of Tobacco: New Tobacco Products” by the KDCA, the usage rate of ENDS among individuals in their 20s rose from 1% in 2013 to 8% in 2021. Moreover, HTPs sales increased from 440 million packs in 2021 to 540 million packs in 2022, marking a 21.3% rise [4]. However, aerosols released by new tobacco products are not simply harmless water vapor; they contain nicotine, carbonyl compounds, volatile organic compounds, propylene glycol, and flavoring additives. These substances differ from those found in traditional cigarettes and can be harmful [4]. Additionally, recent ENDS contain synthetic nicotine, which is produced through an artificial process [5]. However, the impact of smoking on health varies significantly depending on an individual’s smoking habits, and the only presence of harmful chemicals, such as carcinogens, is not, by itself, sufficient to fully assess the extent of harm caused by smoking to the human body. Therefore, behavioral surveys are essential to understand changes in smoking behaviors and habits, as well as experiment-based research to gather scientific evidence on the effects of smoking on health at various levels of exposure.

Table 1. The harmful effect on human health by smoking
ClassDisease causing
by directly smoking
Disease causing
by indirectly smoking
CancerLung cancer, esophageal cancer,
head and neck cancer, pancreatic cancer, stomach cancer, colon cancer, cervical cancer, etc.
Lung cancer, etc.
Cardiovascular diseaseMyocardial infarction, ischemic heart disease, aortic aneurysm, heart failure, disease-related heart attack, stroke, cerebral aneurysm, etc.Coronary artery disease, stroke, worsening of heart disease, etc.
Respiratory diseaseChronic obstructive pulmonary disease, asthma, tuberculosisAggravation of asthma and lung disease, adolescent lung dysfunction, cold, pneumonia, acute lower respiratory disease, etc.
Digestive diseasesCrohn's disease, irritable bowel syndrome, gastroesophageal reflux disease, etc.-
Reproductive diseasesCongenital malformations, fetal development disorders, hypertensive diseases during pregnancy, male sexual dysfunction, etc.Reduced female reproductive function, increased risk of sudden infant death syndrome
Eye diseaseIncreased risk of cataracts, macular degeneration, etc.-
Other diseasePeriodontal disease, diabetes, rheumatoid arthritisIncreased risk of otitis media


To date, studies on the harmful effects of smoking have mostly been cell studies or animal experiments that focus on inhalation toxicity testing. However, the United States and Europe have revised their laws to mandate the assessment of the effects of smoking using in vitro alternatives to animal testing. In the ROK, the legislative process for the “Revision of Alternatives to Animal Experiments” is also in progress. Therefore, a thorough review of the laws concerning alternatives to animal testing is needed. Proposed alternatives to animal testing include organoids, which are three-dimensional (3D) structures of cells derived from organs and stem cells. Organoids have been used to study various aspects of cellular processes, such as cell-to-cell interactions, cell development, and homeostasis, and have been applied in disease modeling [6]. The current literature review summarizes the existing literature on lung organoid models for studying the harms of smoking and lung diseases.

1. Current Research on the Harmful Effects of Smoking Using Lung Organoids

Studies on the harmful effects of smoking on lung organoids were searched using relevant keywords in PubMed, a major medical database. Studies published in the last 10 years on lung organoids and smoking-related terms (e.g., smoke or cigarette) were included in the search. For the search method, a ‘systemic literature review’ was used [7]. A search using ‘lung organoids’ as a keyword identified 1,327 studies; however, when ‘smoke’ or ‘cigarette’ were added as additional keywords, the number of relevant studies decreased to 26. After reviewing the titles, abstracts, and full texts, six papers that conducted experiments examining the harmful effects of smoking using lung organoids were identified (Figure 1). Studies examining lung organoids in relation to smoking focused on lung cancer and chronic obstructive pulmonary disease (COPD). These studies explored the effects of smoking on lung organoid development and the underlying mechanisms of smoking-induced lung disease.

Figure 1. Search methods of lung organoids and smoking study within the last 10 years (PubMed)

In a study on lung cancer, three months of intermittent exposure to cigarette smoke induced lung adenocarcinoma and severe emphysema in mice. After dissecting the lung tissue from the mice to produce lung organoids, it was found that the organoids from the group intermittently exposed to cigarette smoke were more efficiently developed than those from the group that was continuously exposed. A study reported that fatty acid oxidation is induced in type 2 alveolar cells derived from mice directly exposed to mainstream smoke, leading to increased stemness1) in lung cells. These observations indicate a potential positive correlation between stemness and tumor malignancy [8,9]. Furthermore, a study identified a mechanism of the lung emphysema development based on lung organoids derived from mice exposed to cigarette smoke [10]. It has also been found that cigarette smoke exposure inhibits the normal proliferation and recovery of lung epithelial cells, as well as the differentiation of type 2 alveolar cells and the formation of organoids [11].

A study on COPD found that cigarette smoke exposure induces COPD and related diseases in lung organoids derived from mouse fetuses, demonstrating a relationship between prenatal cigarette smoke exposure and COPD development [12]. Another study investigating the mechanisms involved in lung repair following cigarette smoke exposure revealed a significant reduction in both the size and number of alveolar cell organoids after 14 days of exposure to cigarette smoke extract in human and mouse lung organoids [13]. A study reported a reduction in the expression of liver kinase B1 (LKB1), a tumor suppressor gene, in the lungs of COPD patients and mice exposed to cigarette smoke. This lung organoid culture study demonstrated that suppressing LKB1 expression promotes cell differentiation in the airway and the expression of genes that induce macrophages. The study also confirmed that cigarette smoke is associated with mechanisms that increase mucus secretion in the airways and promote excessive cell proliferation, suggesting a correlation between LKB1 gene expression, smoking, and COPD [14].

Current research on lung organoids and smoking has primarily focused on lung cancer and COPD, as approximately 90% of individuals who die from these diseases are smokers [15]. These studies used lung organoids to investigate the mechanisms underlying the development of COPD and lung cancer, thereby elucidating the root causes of smoking-induced lung damage.

2. Lung-organoid Model for Lung Diseases for Research on the Harms of Smoking

Given the limitations of cell models with short life cycles, air-liquid interface cultures with restricted microenvironment control, organ-on-a-chip models that require specialists and advanced technology, spheroid models that cannot replicate organ and vascular functions, and the ethical, economic, and interspecies heterogeneity issues in animal experiments, organoids have emerged as an ideal model for assessing human toxicity (Table 2) [16]. They can replicate organ structure and function and house a diverse range of cell types. Lung organoids utilize cells from various regions of the respiratory system and can replicate the structure, mucus secretion, ciliary movement, and regeneration of alveolar cells (Figure 2). Therefore, researchers have focused on lung organoids as a model for studying the lung, which is the first organ to be damaged by smoking [17]. In this context, the current study conducted a systematic literature review of research utilizing lung organoids to investigate major lung diseases, such as lung cancer, COPD, and pulmonary fibrosis (PF), aiming to evaluate the potential of lung organoids in studies on the harmful effects of smoking.

Figure 2. Types of lung organoids depending on formation method and cell composition
3D=three-dimensional. Reused from the article of Demchenko et al. (Cell Tissue Res 2022;390:317-33) [17].

Table 2. Advantages and disadvantages of biological models to evaluate risk assessment by smoking hazards
ClassAdvantageDisadvantage
2D cell lines

Economical test cost

Easy reproducibility

Simple and easy test method

Test of a short time

Easy high-throughput screening (HTS)

Limitation of the completely mimic primary cell

Unstable gene

Limitation of the test by short cell division and death cycle

Limited number of models or types

Low sensitivity to entering and replicating of viruses

Limitation of interaction confirmation due to absence of stroma, blood vessels, inflammatory cells, etc.

Air-liquid interface

Mimicking the structure and function of human tissue barriers

Possibility of an alternative to animal testing such as skin toxicity

Possibility of realistic exposure conditions

Non-standardization of culture and testing methods

Limitations of in vivo structures reproduction

Limitations of microenvironment control during culture and testing

Organ-on-a-chip

Control of microenvironment during culture and testing

Mimicking the action of organ-to-capillary

Non-standardization of culture and testing methods

Requires experts, advanced technology, and long-term time

Expensive cost due to complex design and manufacturing

Impossible HTS

Spheroids

Possibility to check cell-to-cell interactions and physiological effect

Easy reproducibility

Easy HTS

Difficulty of control the size

Impossible mimicking the action of organ-to-capillary

Complex of formation method

Animal models

Possibility of understanding disease by physiological similarity to humans

Confirmation of interaction due to stroma, blood vessels, inflammatory cells, etc.

High cost and labor

Test of a long time

Bioethical issues

Genetic and anatomical differences on humans and animals

Organoids

Reproduction of the structural and functional of major organs

Possibility of diseases modeling

Possibility of various cells complex

Stable gene

Long-term storage in Biobank

Maintain the characteristics of the original species

Useful of HTS

Non-standardization of culture and testing methods

Lack of reproduction of blood vessels and immune system

Limitations of microenvironment control

Limitations on diffusion of nutrients and metabolites into organoids

2D=two-dimensional.



1) Lung cancer

Lung cancer is a leading cause of cancer-related deaths worldwide, and smoking is a major risk factor. Carcinogens and toxic substances in cigarette smoke affect all regions of the lungs. Numerous studies have confirmed the harmful effects of carcinogens in cigarette smoke, including nicotine, which induces addiction and affects genetic toxicity and the immune system; nitrosamines, cigarette-specific substances derived from nicotine that reduce reproductive function; polycyclic aromatic hydrocarbons, which induce gene mutations; benzene, which damages bone and impairs reproductive function; and acetaldehyde, which irritates the airway and skin [18-21]. However, given the complexity and variability of the mechanisms underlying the progression and treatment of lung cancer, further research is required. This study summarizes research using lung organoids through in vitro methods, which can serve as alternatives to in vivo models.

As presented in Figure 1, a systematic literature review was conducted to identify studies published in the past 10 years that focused on lung organoids in cancer research. A total of 611 studies were initially identified. After excluding literature reviews and carefully reviewing the titles, abstracts, and full texts, 42 studies were found to be suitable for inclusion, and their details are as follows.

Studies on lung cancer and organoids have employed lung cancer cells or tissues from patients with non-small cell lung cancer [22,23], lung adenocarcinoma [24,25], and squamous cell carcinoma [26] and have proposed efficient methods for producing and culturing these organoids [27-31]. Most studies have used lung cancer organoid models for high-throughput screening to select drug candidates for treating lung cancer and have proposed methods for this process [32-39]. Additionally, some studies have examined the underlying mechanisms of action of various anti-cancer drugs, including cisplatin [40], pyrotinib [41], alectinib [42], and halofuginone [43]. Other studies have used lung cancer organoids derived from patients to confirm their potential in identifying optimized treatments and to suggest their clinical applicability [44,45]. Other studies have also examined the general characteristics of lung cancer organoids [46,47], confirmed their feasibility as disease models [48,49], and explored their association with the immune system [50].

Lung cancer organoids preserve the genetic expression information of the originating source and can replicate the structure and microenvironment of lung cancer tissues. Therefore, they are actively used in research on the complexities of lung cancer and personalized treatment. Leveraging the characteristics of patient-derived lung cancer organoids facilitates the investigation of the impact of smoking on lung cancer development across diverse genetic profiles. These organoids offer a promising model for uncovering the underlying mechanisms by which smoking drives lung cancer progression.

2) COPD

COPD is a complex lung disorder accompanied by chronic bronchitis, emphysema, and mucorrhea, which results in damage to the alveolar parenchyma. New treatments and drug development for COPD depend heavily on preclinical models; however, these models have limitations, including high costs and an inability to accurately replicate the structural complexity of the human lung, which poses a challenge for research [51]. To address these limitations, there is ongoing research on the use of lung organoids to investigate the pathogenesis of COPD. This systematic literature review includes studies published in the past 10 years related to lung organoids and COPD. A total of 57 studies were reviewed, 22 of which were deemed suitable for inclusion. Details of these studies are summarized below.

Most studies on COPD have used type 2 alveolar cells to generate lung organoids. In these studies, inhibiting the expression of specific genes in lung organoids (such as rho-kinase 1/2 [52], frizzled receptor 4 [11], mitogenactivated protein kinase 13 [53,54], interleukin-1β [55], interleukin-11 [56], receptor-interacting protein kinase 3 [57], WNT-5A/5B [58], and LL-37 [59]) resulted in impaired fibroblast function, reduced regenerative capacity of damaged lung cells, and increased lung cell deformation. In one study, COPD lung organoids were derived from cells isolated from the nasopharynx and bronchi of patients with COPD. This model successfully reproduced key features of COPD, including goblet cell hyperplasia, reduced ciliary movement, and increased susceptibility to viruses and bacteria [56]. In another study, lung progenitor cells2) were isolated from cystic fibrosis patients and used to generate a COPD lung organoid model [60]. Additionally, it was reported that plastics inhaled from fibrous materials inhibit the differentiation of airway epithelial cells, impairing the repair of lung cells and potentially leading to COPD [61].

Most studies included in this systematic literature review suggested that diverse structural abnormalities in lung tissues, resembling those observed in fibrosis and indicating lung cell deformation and dysfunction, may contribute to the development of COPD. The exposure of organoids to mainstream/sidestream smoke, resulting in cell deformation and dysfunction, could provide valuable insights into various aspects of smoking-induced COPD pathogenesis.

3) Pulmonary fibrosis

PF is a lung disease characterized by repeated damage to the lung epithelium, leading to the hardening of lung tissue (fibrosis) and resulting in severe breathing difficulties. Drugs can delay fibrosis but cannot completely restore damaged lung cells. Smoking is a major cause of PF [62]. This systematic literature review searched for studies published in the last 10 years on lung organoids and PF. A total of 137 studies were reviewed, 42 of which were deemed suitable for inclusion. Given the similar mechanisms underlying COPD and PF, many studies grouped them together, and duplicate studies were excluded during the review. Key findings from these studies are summarized below.

Similar to studies on COPD, studies on PF have also used type 2 alveolar cells to generate lung organoids [63]. However, PF differs from COPD in that it is a chronic, progressive disease characterized by widespread accumulation of extracellular matrix, irreversible damage to alveolar cells, and cellular aging [64]. Studies in which PF was induced have primarily employed anti-cancer antibiotics, such as bleomycin and transforming growth factor-beta (TGF-β). Lung organoids treated with bleomycin replicate the pathogenic characteristics of PF, including epithelial cell-mediated activation of fibroblasts and cellular aging [65]. Additionally, exposing alveolar epithelial cells to TGF-β induces epithelial-mesenchymal transition, triggering the onset of PF [66]. The PF models are distinguished from others that they employed bioprinting to create 3D. Using bioprinting to create a 3D alveolar cell wall model and exposing it to fibrosis-inducing cytokines, a previous study induced structural changes, impaired alveolar cell function, and triggered epithelial-mesenchymal transition, thus validating the model as a suitable fibrosis model [67].

Studies developing PF models with lung organoids have employed various approaches, notably bioprinting, to create consistent PF models that overcome the limitations of traditional organoids. However, as no study has thoroughly investigated the mechanism by which smoking causes PF to be a chronic progressive disease, further research is needed.

4) Respiratory viral infections

Smoking damages type 2 alveolar cells. As viruses typically target airway epithelial and type 2 alveolar cells, the damage caused by smoking may be further exacerbated. Cigarette smoke disrupts the normal functioning of the immune system, weakening its antiviral defense [68]. This systematic literature review searched for studies published in the last 10 years related to lung organoids and viral infections. A total of 156 studies were reviewed, 63 of which were deemed eligible for inclusion.

Recent studies on respiratory viral infections using lung organoids have predominantly focused on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These studies used lung organoid models infected with SARS-CoV-2 to create a viral infection model, examining cellular structural changes along with alterations in protein and gene expression. Benzo[a]pyrene, a component of cigarette smoke, has been shown to increase the susceptibility of lung organoids and type 2 alveolar cells to SARS-CoV-2 infection [69]. Additionally, human lung organoids infected with respiratory syncytial virus (RSV) were used to replicate pathological changes, including alterations in the lung epithelium, cell structures, and syncytium formation, enabling the investigation of the underlying mechanisms [70]. A study examining the correlation between RSV infection and particulate matter (PM) reported increased DNA damage and apoptosis in lung organoids infected with RSV after PM exposure [71]. This finding suggests that external stress applied to virus-infected lung tissues can lead to severe lung damage. A study supports the finding that lung organoids, owing to their ability to replicate lung structures, are well suited for studying cellular responses resulting from interactions between the virus and the host [72].

As both smoking and viral infections target type 2 alveolar cells, this commonality highlights the value of using lung organoid models derived from these cells. Studies indicate that smokers are exposed to high levels of PM, which can trigger varying toxicity responses depending on particle size [73]. Additionally, PM exposure has been shown to increase apoptosis in lung organoids infected with RSV, highlighting the need for further research on the correlation between smoking and respiratory viral infection. This systematic literature review underscores the need for additional research on the relationship between smoking and respiratory viral infections using lung organoids.

Although smoking is known to induce various diseases, research investigating its mechanisms through animal experiments and cell models encounters physical, ethical, physiological, and biological limitations. To overcome these limitations, organoids have been proposed as a model, with the lung—the first organ damaged by smoking—being examined as the primary target. This study, which investigated the current state of research on the harms of smoking using lung organoids, found that most studies focused on organoid models related to lung cancer and COPD but did not incorporate animal experiments or utilize a diverse range of lung disease organoids. Given the high mortality rates from lung cancer and COPD, the studies lacked diversity in their approaches. Thus, this systematic literature review explored the applicability of lung organoids in research examining the harmful effects of smoking by reviewing existing studies on lung cancer, COPD, PF, and infectious respiratory diseases that utilized lung organoids.

The majority of studies have used lung cancer cells to develop organoids that replicate the structure of lung tissues or employed lung cancer organoids derived from the lung tissues of cancer patients. These organoids have been used in anti-cancer drug screening and to assess their clinical applicability in developing effective treatments. A COPD organoid model mimicking patient lung tissues was developed and used to identify genes contributing to COPD induction and to examine cell functional characteristics. PF has often been studied alongside COPD, but unlike COPD, it is characterized by extracellular matrix accumulation, irreversible damage to alveolar cells, and cellular aging, rather than changes in cell function. Studies have identified key chemicals that induce PF and have proposed 3D bioprinting as a solution to overcome the limitations of organoids. Research on lung organoids in response to the global SARS-CoV-2 pandemic is particularly active. One study examined the correlation between RSV infection and PM, confirming the need for further research on PM (fine PM, including tar) produced in large quantities during smoking. The findings from studies modeling lung cancer, COPD, PF, and viral respiratory infections using lung organoids highlight the potential of lung organoids for various applications in research on the harmful effects of smoking, including traditional cigarettes and new tobacco products.

The Smoking Harms Cell Laboratory of the KDCA has conducted research to identify biological markers in lung organoids derived from lung cancer patients and to develop lung organoids that replicate smoking-related lung diseases. In the study, organoids were isolated from surgical tissues of lung cancer patients, and culture conditions were optimized to confirm that the organoids originated from primary cancerous tumors. The cilia, a characteristic feature of lung cells, were examined, and next-generation sequencing was conducted to validate the lung organoid and lung cancer organoid models. Based on this study, research using lung organoids to overcome the limitations of traditional cell and animal models is expected to continue. Since the impact of smoking on health can vary based on personal use patterns, such as frequency, product type, and overall smoking habits, long-term follow-up studies on changes in smokers’ behaviors and the levels of harmful substances present in their bodies will be incorporated into experimental models of smoking-related harm.

1) Although most tissues have a limited capacity for repair following damage, excessive stemness can promote unlimited self-renewal. These findings suggest that when stemness is induced in cells other than cancer or stem cells, there is a high likelihood of these cells transforming into cancerous cells.

2) Cells in the stage prior to differentiating into specialized lung cells with their final function.

Ethics Statement: Not applicable.

Funding Source: None.

Acknowledgments: None.

Conflict of Interest: The authors have no conflicts of interest to declare.

Author Contributions: Conceptualization: REG. Data curation: SMS, YJK, YAJ. Supervision: YJA. Writing – original draft: REG. Writing – review & editing: KIN, YJA, REG.

  1. Korea Disease Control and Prevention Agency. Intergrated report on the harmful effects of tobacco. Cheongju: Korea Disease Control and Prevention Agency; 2022 Dec. Report No.: 11-1790387-000637-12.
  2. Korea Disease Control and Prevention Agency. Korea health statistics 2021: Korea National Health and Nutrition Examination Survey (KNHANES VIII-3). Korea Disease Control and Prevention Agency; 2022.
  3. Zare S, Nemati M, Zheng Y. A systematic review of consumer preference for e-cigarette attributes: flavor, nicotine strength, and type. PLoS One 2018;13:e0194145.
    Pubmed KoreaMed CrossRef
  4. Korea Disease Control and Prevention Agency. Tobacco harm planning report: new type of cigarette. Cheongju: Korea Disease Control and Prevention Agency; 2023 Dec. Report No.: 11-1790387-000883-01.
  5. Jordt SE. Synthetic nicotine has arrived. Tob Control 2023;32(e1):e113-7.
    Pubmed KoreaMed CrossRef
  6. Lu T, Cao Y, Zhao P, Shen S, Xi Y. Organoid: a powerful tool to study lung regeneration and disease. Cell Regen 2021;10:21.
    Pubmed KoreaMed CrossRef
  7. Dyson J, Bhatnagar M, Skinner J, Crooks M. Helping the quitters quit: a systematic review and narrative synthesis of the barriers and facilitators to e-cigarette cessation and the support that is needed. Patient Educ Couns 2022;105:1402-10.
    Pubmed KoreaMed CrossRef
  8. Kameyama N, Chubachi S, Hegab AE, et al. Intermittent exposure to cigarette smoke increases lung tumors and the severity of emphysema more than continuous exposure. Am J Respir Cell Mol Biol 2018;59:179-88.
    Pubmed KoreaMed CrossRef
  9. Irie H, Ozaki M, Chubachi S, et al. Short-term intermittent cigarette smoke exposure enhances alveolar type 2 cell stemness via fatty acid oxidation. Respir Res 2022;23:41.
    Pubmed KoreaMed CrossRef
  10. Jiang Z, Lao T, Qiu W, et al. A chronic obstructive pulmonary disease susceptibility gene, FAM13A, regulates protein stability of β-catenin. Am J Respir Crit Care Med 2016;194:185-97.
    Pubmed KoreaMed CrossRef
  11. Skronska-Wasek W, Mutze K, Baarsma HA, et al. Reduced frizzled receptor 4 expression prevents WNT/β-catenin-driven alveolar lung repair in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196:172-85.
    Pubmed KoreaMed CrossRef
  12. Lkhagvadorj K, Zeng Z, Song J, et al. Prenatal smoke exposure dysregulates lung epithelial cell differentiation in mouse offspring: role for AREG-induced EGFR signaling. Am J Physiol Lung Cell Mol Physiol 2020;319:L742-51.
    Pubmed KoreaMed CrossRef
  13. Zuo WL, Yang J, Gomi K, Chao I, Crystal RG, Shaykhiev R. EGF-amphiregulin interplay in airway stem/progenitor cells links the pathogenesis of smoking-induced lesions in the human airway epithelium. Stem Cells 2017;35:824-37.
    Pubmed KoreaMed CrossRef
  14. Li Y, Zhang Q, Li L, et al. LKB1 deficiency upregulates RELM-α to drive airway goblet cell metaplasia. Cell Mol Life Sci 2021;79:42.
    Pubmed KoreaMed CrossRef
  15. Elicker BM, Kallianos KG, Jones KD, Henry TS. Smoking-related lung disease. Semin Ultrasound CT MR 2019;40:229-38.
    Pubmed KoreaMed CrossRef
  16. Agraval H, Chu HW. Lung organoids in smoking research: current advances and future promises. Biomolecules 2022;12:1463.
    Pubmed KoreaMed CrossRef
  17. Demchenko A, Lavrov A, Smirnikhina S. Lung organoids: current strategies for generation and transplantation. Cell Tissue Res 2022;390:317-33.
    Pubmed KoreaMed CrossRef
  18. Balbo S, James-Yi S, Johnson CS, et al. (S)-N'-nitrosonornicotine, a constituent of smokeless tobacco, is a powerful oral cavity carcinogen in rats. Carcinogenesis 2013;34:2178-83.
    Pubmed KoreaMed CrossRef
  19. Goldman R, Enewold L, Pellizzari E, et al. Smoking increases carcinogenic polycyclic aromatic hydrocarbons in human lung tissue. Cancer Res 2001;61:6367-71.
  20. Matsumoto M, Yamano S, Senoh H, et al. Carcinogenicity and chronic toxicity of acrolein in rats and mice by two-year inhalation study. Regul Toxicol Pharmacol 2021;121:104863.
    Pubmed KoreaMed CrossRef
  21. Peterson LA, Oram MK, Flavin M, et al. Coexposure to inhaled aldehydes or carbon dioxide enhances the carcinogenic properties of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone in the A/J mouse lung. Chem Res Toxicol 2021;34:723-32.
    Pubmed KoreaMed CrossRef
  22. Shi R, Radulovich N, Ng C, et al. Organoid cultures as preclinical models of non-small cell lung cancer. Clin Cancer Res 2020;26:1162-74.
    Pubmed KoreaMed CrossRef
  23. Sen C, Koloff CR, Kundu S, et al. Development of a small cell lung cancer organoid model to study cellular interactions and survival after chemotherapy. Front Pharmacol 2023;14:1211026.
    Pubmed KoreaMed CrossRef
  24. Ebisudani T, Hamamoto J, Togasaki K, et al. Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma. Cell Rep 2023;42:112212.
    Pubmed KoreaMed CrossRef
  25. Li Z, Qian Y, Li W, et al. Human lung adenocarcinoma-derived organoid models for drug screening. iScience 2020;23:101411.
    Pubmed KoreaMed CrossRef
  26. Hai J, Zhang H, Zhou J, et al. Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy. Clin Cancer Res 2020;26:3431-42.
    Pubmed KoreaMed CrossRef
  27. Wang HM, Zhang CY, Peng KC, et al. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study. Cell Rep Med 2023;4:100911.
    Pubmed KoreaMed CrossRef
  28. Acosta-Plasencia M, He Y, Martínez D, et al. Selection of the most suitable culture medium for patient-derived lung cancer organoids. Cells Tissues Organs. 2024. [Epub] https://doi.org/10.1159/000541274
    Pubmed KoreaMed CrossRef
  29. Choi SY, Cho YH, Kim DS, et al. Establishment and long-term expansion of small cell lung cancer patient-derived tumor organoids. Int J Mol Sci 2021;22:1349.
    Pubmed KoreaMed CrossRef
  30. Yamamoto Y, Gotoh S, Korogi Y, et al. Long-term expansion of alveolar stem cells derived from human iPS cells in organoids. Nat Methods 2017;14:1097-106.
    Pubmed KoreaMed CrossRef
  31. Monleón-Guinot I, Milian L, Martínez-Vallejo P, et al. Morphological characterization of human lung cancer organoids cultured in type I collagen hydrogels: a histological approach. Int J Mol Sci 2023;24:10131.
    Pubmed KoreaMed CrossRef
  32. Choi YM, Lee H, Ann M, Song M, Rheey J, Jang J. 3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation. Biofabrication 2023;15:034104.
    Pubmed KoreaMed CrossRef
  33. Kim M, Mun H, Sung CO, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun 2019;10:3991.
    Pubmed KoreaMed CrossRef
  34. Kim SY, Kim SM, Lim S, et al. Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma. Clin Cancer Res 2021;27:4397-409.
    Pubmed KoreaMed CrossRef
  35. Lee SY, Cho HJ, Choi J, et al. Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res 2023;42:309.
    Pubmed KoreaMed CrossRef
  36. Jung DJ, Shin TH, Kim M, Sung CO, Jang SJ, Jeong GS. A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity. Lab Chip 2019;19:2854-65.
    Pubmed KoreaMed CrossRef
  37. Rosell R, Pedraz-Valdunciel C. Lung cancer organoids as avatars of patients with lung cancer in the prediction of therapeutic response. JTO Clin Res Rep 2023;4:100571.
    Pubmed KoreaMed CrossRef
  38. Chen JH, Chu XP, Zhang JT, et al. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. Thorac Cancer 2020;11:2279-90.
    Pubmed KoreaMed CrossRef
  39. Li YF, Gao Y, Liang BW, et al. Patient-derived organoids of non-small cells lung cancer and their application for drug screening. Neoplasma 2020;67:430-7.
    Pubmed KoreaMed CrossRef
  40. Küstermann C, Narbute K, Movčana V, et al. iPSC-derived lung and lung cancer organoid model to evaluate cisplatin encapsulated autologous iPSC-derived mesenchymal stromal cell-isolated extracellular vesicles. Stem Cell Res Ther 2024;15:246.
    Pubmed KoreaMed CrossRef
  41. Wang Y, Jiang T, Qin Z, et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol 2019;30:447-55.
    Pubmed KoreaMed CrossRef
  42. Xie Y, Zhang Y, Wu Y, et al. Analysis of the resistance profile of real-world alectinib first-line therapy in patients with ALK rearrangement-positive advanced non-small cell lung cancer using organoid technology in one case of lung cancer. J Thorac Dis 2024;16:3854-63.
    Pubmed KoreaMed CrossRef
  43. Li H, Zhang Y, Lan X, et al. Halofuginone sensitizes lung cancer organoids to cisplatin via suppressing PI3K/AKT and MAPK signaling pathways. Front Cell Dev Biol 2021;9:773048.
    Pubmed KoreaMed CrossRef
  44. Hu Y, Sui X, Song F, et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nat Commun 2021;12:2581.
    Pubmed KoreaMed CrossRef
  45. Yokota E, Iwai M, Yukawa T, et al. Clinical application of a lung cancer organoid (tumoroid) culture system. NPJ Precis Oncol 2021;5:29.
    Pubmed KoreaMed CrossRef
  46. Oh B, Kim J, Kim N, Jeong Y. Lung cancer organoid system to evaluate the cytotoxicity of natural killer cells. Int J Stem Cells 2024. [Epub] https://doi.org/10.15283/ijsc24021
    CrossRef
  47. Naranjo S, Cabana CM, LaFave LM, et al. Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform. Genes Dev 2022;36:936-49.
    Pubmed KoreaMed CrossRef
  48. Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, et al. Long-term expanding human airway organoids for disease modeling. EMBO J 2019;38:e100300.
    Pubmed KoreaMed CrossRef
  49. Zhang Y, Hu Q, Pei Y, et al. A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments. Nat Commun 2024;15:3382.
    Pubmed KoreaMed CrossRef
  50. Valančiūtė A, Mathieson L, O'Connor RA, et al. Phototherapeutic induction of immunogenic cell death and CD8+ T cell-granzyme B mediated cytolysis in human lung cancer cells and organoids. Cancers (Basel) 2022;14:4119.
    Pubmed KoreaMed CrossRef
  51. Nikolić MZ, Rawlins EL. Lung organoids and their use to study cell-cell interaction. Curr Pathobiol Rep 2017;5:223-31.
    Pubmed KoreaMed CrossRef
  52. Wu X, Verschut V, Woest ME, et al. Rho-kinase 1/2 inhibition prevents transforming growth factor-β-induced effects on pulmonary remodeling and repair. Front Pharmacol 2021;11:609509.
    Pubmed KoreaMed CrossRef
  53. Keeler SP, Wu K, Zhang Y, et al. A potent MAPK13-14 inhibitor prevents airway inflammation and mucus production. Am J Physiol Lung Cell Mol Physiol 2023;325:L726-40.
    Pubmed KoreaMed CrossRef
  54. Wu K, Zhang Y, Mao D, et al. MAPK13 controls structural remodeling and disease after epithelial injury. bioRxiv [Preprint]. 2024 [cited 2024 Oct 15].
    Available from: https://doi.org/10.1101/2024.05.31.596863
    CrossRef
  55. Ciminieri C, Woest ME, Reynaert NL, et al. IL-1β Induces a proinflammatory fibroblast microenvironment that impairs lung progenitors' function. Am J Respir Cell Mol Biol 2023;68:444-55.
    Pubmed KoreaMed CrossRef
  56. Kortekaas RK, Geillinger-Kästle KE, Borghuis T, et al. Interleukin-11 disrupts alveolar epithelial progenitor function. ERJ Open Res 2023;9:00679-2022.
    Pubmed KoreaMed CrossRef
  57. Chen D, Gregory AD, Li X, et al. RIP3-dependent necroptosis contributes to the pathogenesis of chronic obstructive pulmonary disease. JCI Insight 2021;6:e144689.
    Pubmed KoreaMed CrossRef
  58. Wu X, van Dijk EM, Ng-Blichfeldt JP, et al. Mesenchymal WNT-5A/5B signaling represses lung alveolar epithelial progenitors. Cells 2019;8:1147.
    Pubmed KoreaMed CrossRef
  59. Pouwels SD, Hesse L, Wu X, et al. LL-37 and HMGB1 induce alveolar damage and reduce lung tissue regeneration via RAGE. Am J Physiol Lung Cell Mol Physiol 2021;321:L641-52.
    Pubmed KoreaMed CrossRef
  60. Joe YA, Lee MJ, Choi HS. Experimental mouse models and human lung organoid models for studying chronic obstructive pulmonary disease. Biomol Ther (Seoul) 2024;32:685-96.
    Pubmed KoreaMed CrossRef
  61. Song S, van Dijk F, Vasse GF, et al. Inhalable textile microplastic fibers impair airway epithelial differentiation. Am J Respir Crit Care Med 2024;209:427-43.
    Pubmed KoreaMed CrossRef
  62. Oh CK, Murray LA, Molfino NA. Smoking and idiopathic pulmonary fibrosis. Pulm Med 2012;2012:808260.
    Pubmed KoreaMed CrossRef
  63. Suezawa T, Kanagaki S, Moriguchi K, et al. Disease modeling of pulmonary fibrosis using human pluripotent stem cell-derived alveolar organoids. Stem Cell Reports 2021;16:2973-87.
    Pubmed KoreaMed CrossRef
  64. Lee J, Kim JH, Hong SH, Yang SR. Organoid model in idiopathic pulmonary fibrosis. Int J Stem Cells 2021;14:1-8.
    Pubmed KoreaMed CrossRef
  65. Xu Y, Xin W, Yan C, et al. Organoids in lung cancer: a teenager with infinite growth potential. Lung Cancer 2022;172:100-7.
    Pubmed KoreaMed CrossRef
  66. Valdoz JC, Franks NA, Cribbs CG, et al. Soluble ECM promotes organotypic formation in lung alveolar model. Biomaterials 2022;283:121464.
    Pubmed KoreaMed CrossRef
  67. Kang D, Lee Y, Kim W, Lee HR, Jung S. 3D pulmonary fibrosis model for anti-fibrotic drug discovery by inkjet-bioprinting. Biomed Mater 2022;18:015024.
    Pubmed KoreaMed CrossRef
  68. Lee J, Taneja V, Vassallo R. Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res 2012;91:142-9.
    Pubmed KoreaMed CrossRef
  69. Liu W, Zhao Y, Fan J, et al. Smoke and spike: benzo[a]pyrene enhances SARS-CoV-2 infection by boosting NR4A2-induced ACE2 and TMPRSS2 expression. Adv Sci (Weinh) 2023;10:e2300834.
    Pubmed KoreaMed CrossRef
  70. Choi S, Kim EM, Kim SY, et al. Particulate matter exposure exacerbates cellular damage by increasing stress granule formation in respiratory syncytial virus-infected human lung organoids. Environ Pollut 2022;315:120439.
    Pubmed KoreaMed CrossRef
  71. Edwards CE, Tata A, Baric RS. Human lung organoids as a model for respiratory virus replication and countermeasure performance in human hosts. Transl Res 2022;250:36-45.
    Pubmed KoreaMed CrossRef
  72. Chen YW, Huang SX, de Carvalho ALRT, et al. A three-dimensional model of human lung development and disease from pluripotent stem cells. Nat Cell Biol 2017;19:542-9.
    Pubmed KoreaMed CrossRef
  73. Li X, Lin B, Zhang H, et al. Cytotoxicity and mutagenicity of sidestream cigarette smoke particulate matter of different particle sizes. Environ Sci Pollut Res Int 2016;23:2588-94.
    Pubmed KoreaMed CrossRef

Review & Perspective

Public Health Weekly Report 2025; 18(4): 197-221

Published online January 23, 2025 https://doi.org/10.56786/PHWR.2025.18.4.3

Copyright © The Korea Disease Control and Prevention Agency.

Prospects of Smoking Hazards Research Using Lung Organoid

Ryeo-Eun Go , Kyoungin Na , Su-Min Seong , Ye-Ji Kang , Yong Ae Jeong , Younjhin Ahn *

Division of Climate Change and Health Hazard, Department of Health Hazard Response, Korea Disease Control and Prevention Agency, Cheongju, Korea

Correspondence to:*Corresponding author: Younjhin Ahn, Tel: +82-43-219-2950, E-mail: carotene@korea.kr

Received: November 13, 2024; Revised: December 9, 2024; Accepted: December 17, 2024

This is an Open Access aritcle distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Cigarette use is a health hazard that has been reported to reduce life expectancy, increase the risk of death, and result in high socioeconomic costs. New cigarettes increase the ratio of users and reduce the perception of harm to cigarettes by adding liquid nicotine, flavor, and taste. However, aerosols from cigarettes are presumed to be non harmless vapors. Because health effects greatly depend on smokers’ behaviors, the risk of smoking cannot be used to assess the content of harmful chemicals. Accordingly, we conducted an experiment based on behavioral surveys of smokers to evaluate the health effects of exposure to harmful substances. Following this global trend, alternative animal testing methods are proposed to ban animal testing. Therefore, we reviewed the necessity of alternative animal testing for smoking hazards. Organoids are three-dimensional organized cell-derived organs that can be studied in tissues. Therefore, lung organoids can be used as biological tools for smoking hazard research. Six research papers on the current situation of smoking hazard using lung-organoids have been confirmed. These papers discuss the effects of smoking on lung organoids production or pathway study of lung disease by smoking based on the chronic obstructive pulmonary disease. We examined lung organoid-related studies on lung diseases. Eventually, we will apply the results of exposure to harmful substances following smokers’ behaviors from experiments.

Keywords: Smoking hazard, Cigarette, Electronic nicotine delivery systems, Lung-organoids, Lung disease model

Body

Key messages

① What is known previously?

Previously, experiments on smoking hazards have been conducted using cell and animal models for inhalation exposure. Organoids are known to overcome the limitations of cell-organ interactions and ethical issues in animal experiments.

② What new information is presented?

Lung organoids can reproduce parts of organ, depending on their constituent cells. Disease-specific lung organoids can be generated using chemicals, thereby inducing changes in gene expression and stem cells.

③ What are implications?

The lung organoid model can regenerate complex cellular structures and interactions, thereby mimicking the major diseases caused by smoking, may be used in smoking research.

Introduction

Smoking and second-hand smoke are major causes of health issues (Table 1). Continued smoking among lung cancer patients results in a poor prognosis, including an increased risk of recurrence and reduced treatment effectiveness. According to the “Comprehensive Report on the Harms of Tobacco” by the Korea Disease Control and Prevention Agency (KDCA), smoking directly causes approximately 58,000 deaths annually, with associated socioeconomic costs amounting to 12 trillion won [1]. Republic of Korea (ROK) has implemented tobacco control measures, including a national smoking cessation policy, which successfully reduced the smoking rate among adult males from 66% in 1998 to 31% in 2021 [2]. However, with the introduction of new tobacco products such as electronic nicotine delivery systems (ENDS) (2008) and heated tobacco products (HTPs) (2017), the behaviors of cigarette users have been changing significantly. ENDS allow users to customize their nicotine levels, scents, and flavors, which enhances their appeal and potential for abuse (dependence). Additionally, sweet flavors and aromas are known to diminish users’ perceptions of tobacco-related harm [3]. According to the “Report on the Harms of Tobacco: New Tobacco Products” by the KDCA, the usage rate of ENDS among individuals in their 20s rose from 1% in 2013 to 8% in 2021. Moreover, HTPs sales increased from 440 million packs in 2021 to 540 million packs in 2022, marking a 21.3% rise [4]. However, aerosols released by new tobacco products are not simply harmless water vapor; they contain nicotine, carbonyl compounds, volatile organic compounds, propylene glycol, and flavoring additives. These substances differ from those found in traditional cigarettes and can be harmful [4]. Additionally, recent ENDS contain synthetic nicotine, which is produced through an artificial process [5]. However, the impact of smoking on health varies significantly depending on an individual’s smoking habits, and the only presence of harmful chemicals, such as carcinogens, is not, by itself, sufficient to fully assess the extent of harm caused by smoking to the human body. Therefore, behavioral surveys are essential to understand changes in smoking behaviors and habits, as well as experiment-based research to gather scientific evidence on the effects of smoking on health at various levels of exposure.

The harmful effect on human health by smoking
ClassDisease causing
by directly smoking
Disease causing
by indirectly smoking
CancerLung cancer, esophageal cancer,
head and neck cancer, pancreatic cancer, stomach cancer, colon cancer, cervical cancer, etc.
Lung cancer, etc.
Cardiovascular diseaseMyocardial infarction, ischemic heart disease, aortic aneurysm, heart failure, disease-related heart attack, stroke, cerebral aneurysm, etc.Coronary artery disease, stroke, worsening of heart disease, etc.
Respiratory diseaseChronic obstructive pulmonary disease, asthma, tuberculosisAggravation of asthma and lung disease, adolescent lung dysfunction, cold, pneumonia, acute lower respiratory disease, etc.
Digestive diseasesCrohn's disease, irritable bowel syndrome, gastroesophageal reflux disease, etc.-
Reproductive diseasesCongenital malformations, fetal development disorders, hypertensive diseases during pregnancy, male sexual dysfunction, etc.Reduced female reproductive function, increased risk of sudden infant death syndrome
Eye diseaseIncreased risk of cataracts, macular degeneration, etc.-
Other diseasePeriodontal disease, diabetes, rheumatoid arthritisIncreased risk of otitis media


To date, studies on the harmful effects of smoking have mostly been cell studies or animal experiments that focus on inhalation toxicity testing. However, the United States and Europe have revised their laws to mandate the assessment of the effects of smoking using in vitro alternatives to animal testing. In the ROK, the legislative process for the “Revision of Alternatives to Animal Experiments” is also in progress. Therefore, a thorough review of the laws concerning alternatives to animal testing is needed. Proposed alternatives to animal testing include organoids, which are three-dimensional (3D) structures of cells derived from organs and stem cells. Organoids have been used to study various aspects of cellular processes, such as cell-to-cell interactions, cell development, and homeostasis, and have been applied in disease modeling [6]. The current literature review summarizes the existing literature on lung organoid models for studying the harms of smoking and lung diseases.

Main

1. Current Research on the Harmful Effects of Smoking Using Lung Organoids

Studies on the harmful effects of smoking on lung organoids were searched using relevant keywords in PubMed, a major medical database. Studies published in the last 10 years on lung organoids and smoking-related terms (e.g., smoke or cigarette) were included in the search. For the search method, a ‘systemic literature review’ was used [7]. A search using ‘lung organoids’ as a keyword identified 1,327 studies; however, when ‘smoke’ or ‘cigarette’ were added as additional keywords, the number of relevant studies decreased to 26. After reviewing the titles, abstracts, and full texts, six papers that conducted experiments examining the harmful effects of smoking using lung organoids were identified (Figure 1). Studies examining lung organoids in relation to smoking focused on lung cancer and chronic obstructive pulmonary disease (COPD). These studies explored the effects of smoking on lung organoid development and the underlying mechanisms of smoking-induced lung disease.

Figure 1. Search methods of lung organoids and smoking study within the last 10 years (PubMed)

In a study on lung cancer, three months of intermittent exposure to cigarette smoke induced lung adenocarcinoma and severe emphysema in mice. After dissecting the lung tissue from the mice to produce lung organoids, it was found that the organoids from the group intermittently exposed to cigarette smoke were more efficiently developed than those from the group that was continuously exposed. A study reported that fatty acid oxidation is induced in type 2 alveolar cells derived from mice directly exposed to mainstream smoke, leading to increased stemness1) in lung cells. These observations indicate a potential positive correlation between stemness and tumor malignancy [8,9]. Furthermore, a study identified a mechanism of the lung emphysema development based on lung organoids derived from mice exposed to cigarette smoke [10]. It has also been found that cigarette smoke exposure inhibits the normal proliferation and recovery of lung epithelial cells, as well as the differentiation of type 2 alveolar cells and the formation of organoids [11].

A study on COPD found that cigarette smoke exposure induces COPD and related diseases in lung organoids derived from mouse fetuses, demonstrating a relationship between prenatal cigarette smoke exposure and COPD development [12]. Another study investigating the mechanisms involved in lung repair following cigarette smoke exposure revealed a significant reduction in both the size and number of alveolar cell organoids after 14 days of exposure to cigarette smoke extract in human and mouse lung organoids [13]. A study reported a reduction in the expression of liver kinase B1 (LKB1), a tumor suppressor gene, in the lungs of COPD patients and mice exposed to cigarette smoke. This lung organoid culture study demonstrated that suppressing LKB1 expression promotes cell differentiation in the airway and the expression of genes that induce macrophages. The study also confirmed that cigarette smoke is associated with mechanisms that increase mucus secretion in the airways and promote excessive cell proliferation, suggesting a correlation between LKB1 gene expression, smoking, and COPD [14].

Current research on lung organoids and smoking has primarily focused on lung cancer and COPD, as approximately 90% of individuals who die from these diseases are smokers [15]. These studies used lung organoids to investigate the mechanisms underlying the development of COPD and lung cancer, thereby elucidating the root causes of smoking-induced lung damage.

2. Lung-organoid Model for Lung Diseases for Research on the Harms of Smoking

Given the limitations of cell models with short life cycles, air-liquid interface cultures with restricted microenvironment control, organ-on-a-chip models that require specialists and advanced technology, spheroid models that cannot replicate organ and vascular functions, and the ethical, economic, and interspecies heterogeneity issues in animal experiments, organoids have emerged as an ideal model for assessing human toxicity (Table 2) [16]. They can replicate organ structure and function and house a diverse range of cell types. Lung organoids utilize cells from various regions of the respiratory system and can replicate the structure, mucus secretion, ciliary movement, and regeneration of alveolar cells (Figure 2). Therefore, researchers have focused on lung organoids as a model for studying the lung, which is the first organ to be damaged by smoking [17]. In this context, the current study conducted a systematic literature review of research utilizing lung organoids to investigate major lung diseases, such as lung cancer, COPD, and pulmonary fibrosis (PF), aiming to evaluate the potential of lung organoids in studies on the harmful effects of smoking.

Figure 2. Types of lung organoids depending on formation method and cell composition
3D=three-dimensional. Reused from the article of Demchenko et al. (Cell Tissue Res 2022;390:317-33) [17].

Advantages and disadvantages of biological models to evaluate risk assessment by smoking hazards
ClassAdvantageDisadvantage
2D cell lines

Economical test cost.

Easy reproducibility.

Simple and easy test method.

Test of a short time.

Easy high-throughput screening (HTS).

Limitation of the completely mimic primary cell.

Unstable gene.

Limitation of the test by short cell division and death cycle.

Limited number of models or types.

Low sensitivity to entering and replicating of viruses.

Limitation of interaction confirmation due to absence of stroma, blood vessels, inflammatory cells, etc..

Air-liquid interface

Mimicking the structure and function of human tissue barriers.

Possibility of an alternative to animal testing such as skin toxicity.

Possibility of realistic exposure conditions.

Non-standardization of culture and testing methods.

Limitations of in vivo structures reproduction.

Limitations of microenvironment control during culture and testing.

Organ-on-a-chip

Control of microenvironment during culture and testing.

Mimicking the action of organ-to-capillary.

Non-standardization of culture and testing methods.

Requires experts, advanced technology, and long-term time.

Expensive cost due to complex design and manufacturing.

Impossible HTS.

Spheroids

Possibility to check cell-to-cell interactions and physiological effect.

Easy reproducibility.

Easy HTS.

Difficulty of control the size.

Impossible mimicking the action of organ-to-capillary.

Complex of formation method.

Animal models

Possibility of understanding disease by physiological similarity to humans.

Confirmation of interaction due to stroma, blood vessels, inflammatory cells, etc..

High cost and labor.

Test of a long time.

Bioethical issues.

Genetic and anatomical differences on humans and animals.

Organoids

Reproduction of the structural and functional of major organs.

Possibility of diseases modeling.

Possibility of various cells complex.

Stable gene.

Long-term storage in Biobank.

Maintain the characteristics of the original species.

Useful of HTS.

Non-standardization of culture and testing methods.

Lack of reproduction of blood vessels and immune system.

Limitations of microenvironment control.

Limitations on diffusion of nutrients and metabolites into organoids.

2D=two-dimensional..



1) Lung cancer

Lung cancer is a leading cause of cancer-related deaths worldwide, and smoking is a major risk factor. Carcinogens and toxic substances in cigarette smoke affect all regions of the lungs. Numerous studies have confirmed the harmful effects of carcinogens in cigarette smoke, including nicotine, which induces addiction and affects genetic toxicity and the immune system; nitrosamines, cigarette-specific substances derived from nicotine that reduce reproductive function; polycyclic aromatic hydrocarbons, which induce gene mutations; benzene, which damages bone and impairs reproductive function; and acetaldehyde, which irritates the airway and skin [18,,-21]. However, given the complexity and variability of the mechanisms underlying the progression and treatment of lung cancer, further research is required. This study summarizes research using lung organoids through in vitro methods, which can serve as alternatives to in vivo models.

As presented in Figure 1, a systematic literature review was conducted to identify studies published in the past 10 years that focused on lung organoids in cancer research. A total of 611 studies were initially identified. After excluding literature reviews and carefully reviewing the titles, abstracts, and full texts, 42 studies were found to be suitable for inclusion, and their details are as follows.

Studies on lung cancer and organoids have employed lung cancer cells or tissues from patients with non-small cell lung cancer [22,23], lung adenocarcinoma [24,25], and squamous cell carcinoma [26] and have proposed efficient methods for producing and culturing these organoids [27,,,-31]. Most studies have used lung cancer organoid models for high-throughput screening to select drug candidates for treating lung cancer and have proposed methods for this process [32,,,,,,-39]. Additionally, some studies have examined the underlying mechanisms of action of various anti-cancer drugs, including cisplatin [40], pyrotinib [41], alectinib [42], and halofuginone [43]. Other studies have used lung cancer organoids derived from patients to confirm their potential in identifying optimized treatments and to suggest their clinical applicability [44,45]. Other studies have also examined the general characteristics of lung cancer organoids [46,47], confirmed their feasibility as disease models [48,49], and explored their association with the immune system [50].

Lung cancer organoids preserve the genetic expression information of the originating source and can replicate the structure and microenvironment of lung cancer tissues. Therefore, they are actively used in research on the complexities of lung cancer and personalized treatment. Leveraging the characteristics of patient-derived lung cancer organoids facilitates the investigation of the impact of smoking on lung cancer development across diverse genetic profiles. These organoids offer a promising model for uncovering the underlying mechanisms by which smoking drives lung cancer progression.

2) COPD

COPD is a complex lung disorder accompanied by chronic bronchitis, emphysema, and mucorrhea, which results in damage to the alveolar parenchyma. New treatments and drug development for COPD depend heavily on preclinical models; however, these models have limitations, including high costs and an inability to accurately replicate the structural complexity of the human lung, which poses a challenge for research [51]. To address these limitations, there is ongoing research on the use of lung organoids to investigate the pathogenesis of COPD. This systematic literature review includes studies published in the past 10 years related to lung organoids and COPD. A total of 57 studies were reviewed, 22 of which were deemed suitable for inclusion. Details of these studies are summarized below.

Most studies on COPD have used type 2 alveolar cells to generate lung organoids. In these studies, inhibiting the expression of specific genes in lung organoids (such as rho-kinase 1/2 [52], frizzled receptor 4 [11], mitogenactivated protein kinase 13 [53,54], interleukin-1β [55], interleukin-11 [56], receptor-interacting protein kinase 3 [57], WNT-5A/5B [58], and LL-37 [59]) resulted in impaired fibroblast function, reduced regenerative capacity of damaged lung cells, and increased lung cell deformation. In one study, COPD lung organoids were derived from cells isolated from the nasopharynx and bronchi of patients with COPD. This model successfully reproduced key features of COPD, including goblet cell hyperplasia, reduced ciliary movement, and increased susceptibility to viruses and bacteria [56]. In another study, lung progenitor cells2) were isolated from cystic fibrosis patients and used to generate a COPD lung organoid model [60]. Additionally, it was reported that plastics inhaled from fibrous materials inhibit the differentiation of airway epithelial cells, impairing the repair of lung cells and potentially leading to COPD [61].

Most studies included in this systematic literature review suggested that diverse structural abnormalities in lung tissues, resembling those observed in fibrosis and indicating lung cell deformation and dysfunction, may contribute to the development of COPD. The exposure of organoids to mainstream/sidestream smoke, resulting in cell deformation and dysfunction, could provide valuable insights into various aspects of smoking-induced COPD pathogenesis.

3) Pulmonary fibrosis

PF is a lung disease characterized by repeated damage to the lung epithelium, leading to the hardening of lung tissue (fibrosis) and resulting in severe breathing difficulties. Drugs can delay fibrosis but cannot completely restore damaged lung cells. Smoking is a major cause of PF [62]. This systematic literature review searched for studies published in the last 10 years on lung organoids and PF. A total of 137 studies were reviewed, 42 of which were deemed suitable for inclusion. Given the similar mechanisms underlying COPD and PF, many studies grouped them together, and duplicate studies were excluded during the review. Key findings from these studies are summarized below.

Similar to studies on COPD, studies on PF have also used type 2 alveolar cells to generate lung organoids [63]. However, PF differs from COPD in that it is a chronic, progressive disease characterized by widespread accumulation of extracellular matrix, irreversible damage to alveolar cells, and cellular aging [64]. Studies in which PF was induced have primarily employed anti-cancer antibiotics, such as bleomycin and transforming growth factor-beta (TGF-β). Lung organoids treated with bleomycin replicate the pathogenic characteristics of PF, including epithelial cell-mediated activation of fibroblasts and cellular aging [65]. Additionally, exposing alveolar epithelial cells to TGF-β induces epithelial-mesenchymal transition, triggering the onset of PF [66]. The PF models are distinguished from others that they employed bioprinting to create 3D. Using bioprinting to create a 3D alveolar cell wall model and exposing it to fibrosis-inducing cytokines, a previous study induced structural changes, impaired alveolar cell function, and triggered epithelial-mesenchymal transition, thus validating the model as a suitable fibrosis model [67].

Studies developing PF models with lung organoids have employed various approaches, notably bioprinting, to create consistent PF models that overcome the limitations of traditional organoids. However, as no study has thoroughly investigated the mechanism by which smoking causes PF to be a chronic progressive disease, further research is needed.

4) Respiratory viral infections

Smoking damages type 2 alveolar cells. As viruses typically target airway epithelial and type 2 alveolar cells, the damage caused by smoking may be further exacerbated. Cigarette smoke disrupts the normal functioning of the immune system, weakening its antiviral defense [68]. This systematic literature review searched for studies published in the last 10 years related to lung organoids and viral infections. A total of 156 studies were reviewed, 63 of which were deemed eligible for inclusion.

Recent studies on respiratory viral infections using lung organoids have predominantly focused on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These studies used lung organoid models infected with SARS-CoV-2 to create a viral infection model, examining cellular structural changes along with alterations in protein and gene expression. Benzo[a]pyrene, a component of cigarette smoke, has been shown to increase the susceptibility of lung organoids and type 2 alveolar cells to SARS-CoV-2 infection [69]. Additionally, human lung organoids infected with respiratory syncytial virus (RSV) were used to replicate pathological changes, including alterations in the lung epithelium, cell structures, and syncytium formation, enabling the investigation of the underlying mechanisms [70]. A study examining the correlation between RSV infection and particulate matter (PM) reported increased DNA damage and apoptosis in lung organoids infected with RSV after PM exposure [71]. This finding suggests that external stress applied to virus-infected lung tissues can lead to severe lung damage. A study supports the finding that lung organoids, owing to their ability to replicate lung structures, are well suited for studying cellular responses resulting from interactions between the virus and the host [72].

As both smoking and viral infections target type 2 alveolar cells, this commonality highlights the value of using lung organoid models derived from these cells. Studies indicate that smokers are exposed to high levels of PM, which can trigger varying toxicity responses depending on particle size [73]. Additionally, PM exposure has been shown to increase apoptosis in lung organoids infected with RSV, highlighting the need for further research on the correlation between smoking and respiratory viral infection. This systematic literature review underscores the need for additional research on the relationship between smoking and respiratory viral infections using lung organoids.

Conclusion

Although smoking is known to induce various diseases, research investigating its mechanisms through animal experiments and cell models encounters physical, ethical, physiological, and biological limitations. To overcome these limitations, organoids have been proposed as a model, with the lung—the first organ damaged by smoking—being examined as the primary target. This study, which investigated the current state of research on the harms of smoking using lung organoids, found that most studies focused on organoid models related to lung cancer and COPD but did not incorporate animal experiments or utilize a diverse range of lung disease organoids. Given the high mortality rates from lung cancer and COPD, the studies lacked diversity in their approaches. Thus, this systematic literature review explored the applicability of lung organoids in research examining the harmful effects of smoking by reviewing existing studies on lung cancer, COPD, PF, and infectious respiratory diseases that utilized lung organoids.

The majority of studies have used lung cancer cells to develop organoids that replicate the structure of lung tissues or employed lung cancer organoids derived from the lung tissues of cancer patients. These organoids have been used in anti-cancer drug screening and to assess their clinical applicability in developing effective treatments. A COPD organoid model mimicking patient lung tissues was developed and used to identify genes contributing to COPD induction and to examine cell functional characteristics. PF has often been studied alongside COPD, but unlike COPD, it is characterized by extracellular matrix accumulation, irreversible damage to alveolar cells, and cellular aging, rather than changes in cell function. Studies have identified key chemicals that induce PF and have proposed 3D bioprinting as a solution to overcome the limitations of organoids. Research on lung organoids in response to the global SARS-CoV-2 pandemic is particularly active. One study examined the correlation between RSV infection and PM, confirming the need for further research on PM (fine PM, including tar) produced in large quantities during smoking. The findings from studies modeling lung cancer, COPD, PF, and viral respiratory infections using lung organoids highlight the potential of lung organoids for various applications in research on the harmful effects of smoking, including traditional cigarettes and new tobacco products.

The Smoking Harms Cell Laboratory of the KDCA has conducted research to identify biological markers in lung organoids derived from lung cancer patients and to develop lung organoids that replicate smoking-related lung diseases. In the study, organoids were isolated from surgical tissues of lung cancer patients, and culture conditions were optimized to confirm that the organoids originated from primary cancerous tumors. The cilia, a characteristic feature of lung cells, were examined, and next-generation sequencing was conducted to validate the lung organoid and lung cancer organoid models. Based on this study, research using lung organoids to overcome the limitations of traditional cell and animal models is expected to continue. Since the impact of smoking on health can vary based on personal use patterns, such as frequency, product type, and overall smoking habits, long-term follow-up studies on changes in smokers’ behaviors and the levels of harmful substances present in their bodies will be incorporated into experimental models of smoking-related harm.

Footnote

1) Although most tissues have a limited capacity for repair following damage, excessive stemness can promote unlimited self-renewal. These findings suggest that when stemness is induced in cells other than cancer or stem cells, there is a high likelihood of these cells transforming into cancerous cells.

2) Cells in the stage prior to differentiating into specialized lung cells with their final function.

Declarations

Ethics Statement: Not applicable.

Funding Source: None.

Acknowledgments: None.

Conflict of Interest: The authors have no conflicts of interest to declare.

Author Contributions: Conceptualization: REG. Data curation: SMS, YJK, YAJ. Supervision: YJA. Writing – original draft: REG. Writing – review & editing: KIN, YJA, REG.

Fig 1.

Figure 1.Search methods of lung organoids and smoking study within the last 10 years (PubMed)
Public Health Weekly Report 2025; 18: 197-221https://doi.org/10.56786/PHWR.2025.18.4.3

Fig 2.

Figure 2.Types of lung organoids depending on formation method and cell composition
3D=three-dimensional. Reused from the article of Demchenko et al. (Cell Tissue Res 2022;390:317-33) [17].
Public Health Weekly Report 2025; 18: 197-221https://doi.org/10.56786/PHWR.2025.18.4.3
The harmful effect on human health by smoking
ClassDisease causing
by directly smoking
Disease causing
by indirectly smoking
CancerLung cancer, esophageal cancer,
head and neck cancer, pancreatic cancer, stomach cancer, colon cancer, cervical cancer, etc.
Lung cancer, etc.
Cardiovascular diseaseMyocardial infarction, ischemic heart disease, aortic aneurysm, heart failure, disease-related heart attack, stroke, cerebral aneurysm, etc.Coronary artery disease, stroke, worsening of heart disease, etc.
Respiratory diseaseChronic obstructive pulmonary disease, asthma, tuberculosisAggravation of asthma and lung disease, adolescent lung dysfunction, cold, pneumonia, acute lower respiratory disease, etc.
Digestive diseasesCrohn's disease, irritable bowel syndrome, gastroesophageal reflux disease, etc.-
Reproductive diseasesCongenital malformations, fetal development disorders, hypertensive diseases during pregnancy, male sexual dysfunction, etc.Reduced female reproductive function, increased risk of sudden infant death syndrome
Eye diseaseIncreased risk of cataracts, macular degeneration, etc.-
Other diseasePeriodontal disease, diabetes, rheumatoid arthritisIncreased risk of otitis media

Advantages and disadvantages of biological models to evaluate risk assessment by smoking hazards
ClassAdvantageDisadvantage
2D cell lines

Economical test cost.

Easy reproducibility.

Simple and easy test method.

Test of a short time.

Easy high-throughput screening (HTS).

Limitation of the completely mimic primary cell.

Unstable gene.

Limitation of the test by short cell division and death cycle.

Limited number of models or types.

Low sensitivity to entering and replicating of viruses.

Limitation of interaction confirmation due to absence of stroma, blood vessels, inflammatory cells, etc..

Air-liquid interface

Mimicking the structure and function of human tissue barriers.

Possibility of an alternative to animal testing such as skin toxicity.

Possibility of realistic exposure conditions.

Non-standardization of culture and testing methods.

Limitations of in vivo structures reproduction.

Limitations of microenvironment control during culture and testing.

Organ-on-a-chip

Control of microenvironment during culture and testing.

Mimicking the action of organ-to-capillary.

Non-standardization of culture and testing methods.

Requires experts, advanced technology, and long-term time.

Expensive cost due to complex design and manufacturing.

Impossible HTS.

Spheroids

Possibility to check cell-to-cell interactions and physiological effect.

Easy reproducibility.

Easy HTS.

Difficulty of control the size.

Impossible mimicking the action of organ-to-capillary.

Complex of formation method.

Animal models

Possibility of understanding disease by physiological similarity to humans.

Confirmation of interaction due to stroma, blood vessels, inflammatory cells, etc..

High cost and labor.

Test of a long time.

Bioethical issues.

Genetic and anatomical differences on humans and animals.

Organoids

Reproduction of the structural and functional of major organs.

Possibility of diseases modeling.

Possibility of various cells complex.

Stable gene.

Long-term storage in Biobank.

Maintain the characteristics of the original species.

Useful of HTS.

Non-standardization of culture and testing methods.

Lack of reproduction of blood vessels and immune system.

Limitations of microenvironment control.

Limitations on diffusion of nutrients and metabolites into organoids.

2D=two-dimensional..


References

  1. Korea Disease Control and Prevention Agency. Intergrated report on the harmful effects of tobacco. Cheongju: Korea Disease Control and Prevention Agency; 2022 Dec. Report No.: 11-1790387-000637-12.
  2. Korea Disease Control and Prevention Agency. Korea health statistics 2021: Korea National Health and Nutrition Examination Survey (KNHANES VIII-3). Korea Disease Control and Prevention Agency; 2022.
  3. Zare S, Nemati M, Zheng Y. A systematic review of consumer preference for e-cigarette attributes: flavor, nicotine strength, and type. PLoS One 2018;13:e0194145.
    Pubmed KoreaMed CrossRef
  4. Korea Disease Control and Prevention Agency. Tobacco harm planning report: new type of cigarette. Cheongju: Korea Disease Control and Prevention Agency; 2023 Dec. Report No.: 11-1790387-000883-01.
  5. Jordt SE. Synthetic nicotine has arrived. Tob Control 2023;32(e1):e113-7.
    Pubmed KoreaMed CrossRef
  6. Lu T, Cao Y, Zhao P, Shen S, Xi Y. Organoid: a powerful tool to study lung regeneration and disease. Cell Regen 2021;10:21.
    Pubmed KoreaMed CrossRef
  7. Dyson J, Bhatnagar M, Skinner J, Crooks M. Helping the quitters quit: a systematic review and narrative synthesis of the barriers and facilitators to e-cigarette cessation and the support that is needed. Patient Educ Couns 2022;105:1402-10.
    Pubmed KoreaMed CrossRef
  8. Kameyama N, Chubachi S, Hegab AE, et al. Intermittent exposure to cigarette smoke increases lung tumors and the severity of emphysema more than continuous exposure. Am J Respir Cell Mol Biol 2018;59:179-88.
    Pubmed KoreaMed CrossRef
  9. Irie H, Ozaki M, Chubachi S, et al. Short-term intermittent cigarette smoke exposure enhances alveolar type 2 cell stemness via fatty acid oxidation. Respir Res 2022;23:41.
    Pubmed KoreaMed CrossRef
  10. Jiang Z, Lao T, Qiu W, et al. A chronic obstructive pulmonary disease susceptibility gene, FAM13A, regulates protein stability of β-catenin. Am J Respir Crit Care Med 2016;194:185-97.
    Pubmed KoreaMed CrossRef
  11. Skronska-Wasek W, Mutze K, Baarsma HA, et al. Reduced frizzled receptor 4 expression prevents WNT/β-catenin-driven alveolar lung repair in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196:172-85.
    Pubmed KoreaMed CrossRef
  12. Lkhagvadorj K, Zeng Z, Song J, et al. Prenatal smoke exposure dysregulates lung epithelial cell differentiation in mouse offspring: role for AREG-induced EGFR signaling. Am J Physiol Lung Cell Mol Physiol 2020;319:L742-51.
    Pubmed KoreaMed CrossRef
  13. Zuo WL, Yang J, Gomi K, Chao I, Crystal RG, Shaykhiev R. EGF-amphiregulin interplay in airway stem/progenitor cells links the pathogenesis of smoking-induced lesions in the human airway epithelium. Stem Cells 2017;35:824-37.
    Pubmed KoreaMed CrossRef
  14. Li Y, Zhang Q, Li L, et al. LKB1 deficiency upregulates RELM-α to drive airway goblet cell metaplasia. Cell Mol Life Sci 2021;79:42.
    Pubmed KoreaMed CrossRef
  15. Elicker BM, Kallianos KG, Jones KD, Henry TS. Smoking-related lung disease. Semin Ultrasound CT MR 2019;40:229-38.
    Pubmed KoreaMed CrossRef
  16. Agraval H, Chu HW. Lung organoids in smoking research: current advances and future promises. Biomolecules 2022;12:1463.
    Pubmed KoreaMed CrossRef
  17. Demchenko A, Lavrov A, Smirnikhina S. Lung organoids: current strategies for generation and transplantation. Cell Tissue Res 2022;390:317-33.
    Pubmed KoreaMed CrossRef
  18. Balbo S, James-Yi S, Johnson CS, et al. (S)-N'-nitrosonornicotine, a constituent of smokeless tobacco, is a powerful oral cavity carcinogen in rats. Carcinogenesis 2013;34:2178-83.
    Pubmed KoreaMed CrossRef
  19. Goldman R, Enewold L, Pellizzari E, et al. Smoking increases carcinogenic polycyclic aromatic hydrocarbons in human lung tissue. Cancer Res 2001;61:6367-71.
  20. Matsumoto M, Yamano S, Senoh H, et al. Carcinogenicity and chronic toxicity of acrolein in rats and mice by two-year inhalation study. Regul Toxicol Pharmacol 2021;121:104863.
    Pubmed KoreaMed CrossRef
  21. Peterson LA, Oram MK, Flavin M, et al. Coexposure to inhaled aldehydes or carbon dioxide enhances the carcinogenic properties of the tobacco-specific nitrosamine 4-methylnitrosamino-1-(3-pyridyl)-1-butanone in the A/J mouse lung. Chem Res Toxicol 2021;34:723-32.
    Pubmed KoreaMed CrossRef
  22. Shi R, Radulovich N, Ng C, et al. Organoid cultures as preclinical models of non-small cell lung cancer. Clin Cancer Res 2020;26:1162-74.
    Pubmed KoreaMed CrossRef
  23. Sen C, Koloff CR, Kundu S, et al. Development of a small cell lung cancer organoid model to study cellular interactions and survival after chemotherapy. Front Pharmacol 2023;14:1211026.
    Pubmed KoreaMed CrossRef
  24. Ebisudani T, Hamamoto J, Togasaki K, et al. Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma. Cell Rep 2023;42:112212.
    Pubmed KoreaMed CrossRef
  25. Li Z, Qian Y, Li W, et al. Human lung adenocarcinoma-derived organoid models for drug screening. iScience 2020;23:101411.
    Pubmed KoreaMed CrossRef
  26. Hai J, Zhang H, Zhou J, et al. Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy. Clin Cancer Res 2020;26:3431-42.
    Pubmed KoreaMed CrossRef
  27. Wang HM, Zhang CY, Peng KC, et al. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study. Cell Rep Med 2023;4:100911.
    Pubmed KoreaMed CrossRef
  28. Acosta-Plasencia M, He Y, Martínez D, et al. Selection of the most suitable culture medium for patient-derived lung cancer organoids. Cells Tissues Organs. 2024. [Epub] https://doi.org/10.1159/000541274
    Pubmed KoreaMed CrossRef
  29. Choi SY, Cho YH, Kim DS, et al. Establishment and long-term expansion of small cell lung cancer patient-derived tumor organoids. Int J Mol Sci 2021;22:1349.
    Pubmed KoreaMed CrossRef
  30. Yamamoto Y, Gotoh S, Korogi Y, et al. Long-term expansion of alveolar stem cells derived from human iPS cells in organoids. Nat Methods 2017;14:1097-106.
    Pubmed KoreaMed CrossRef
  31. Monleón-Guinot I, Milian L, Martínez-Vallejo P, et al. Morphological characterization of human lung cancer organoids cultured in type I collagen hydrogels: a histological approach. Int J Mol Sci 2023;24:10131.
    Pubmed KoreaMed CrossRef
  32. Choi YM, Lee H, Ann M, Song M, Rheey J, Jang J. 3D bioprinted vascularized lung cancer organoid models with underlying disease capable of more precise drug evaluation. Biofabrication 2023;15:034104.
    Pubmed KoreaMed CrossRef
  33. Kim M, Mun H, Sung CO, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nat Commun 2019;10:3991.
    Pubmed KoreaMed CrossRef
  34. Kim SY, Kim SM, Lim S, et al. Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma. Clin Cancer Res 2021;27:4397-409.
    Pubmed KoreaMed CrossRef
  35. Lee SY, Cho HJ, Choi J, et al. Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res 2023;42:309.
    Pubmed KoreaMed CrossRef
  36. Jung DJ, Shin TH, Kim M, Sung CO, Jang SJ, Jeong GS. A one-stop microfluidic-based lung cancer organoid culture platform for testing drug sensitivity. Lab Chip 2019;19:2854-65.
    Pubmed KoreaMed CrossRef
  37. Rosell R, Pedraz-Valdunciel C. Lung cancer organoids as avatars of patients with lung cancer in the prediction of therapeutic response. JTO Clin Res Rep 2023;4:100571.
    Pubmed KoreaMed CrossRef
  38. Chen JH, Chu XP, Zhang JT, et al. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. Thorac Cancer 2020;11:2279-90.
    Pubmed KoreaMed CrossRef
  39. Li YF, Gao Y, Liang BW, et al. Patient-derived organoids of non-small cells lung cancer and their application for drug screening. Neoplasma 2020;67:430-7.
    Pubmed KoreaMed CrossRef
  40. Küstermann C, Narbute K, Movčana V, et al. iPSC-derived lung and lung cancer organoid model to evaluate cisplatin encapsulated autologous iPSC-derived mesenchymal stromal cell-isolated extracellular vesicles. Stem Cell Res Ther 2024;15:246.
    Pubmed KoreaMed CrossRef
  41. Wang Y, Jiang T, Qin Z, et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol 2019;30:447-55.
    Pubmed KoreaMed CrossRef
  42. Xie Y, Zhang Y, Wu Y, et al. Analysis of the resistance profile of real-world alectinib first-line therapy in patients with ALK rearrangement-positive advanced non-small cell lung cancer using organoid technology in one case of lung cancer. J Thorac Dis 2024;16:3854-63.
    Pubmed KoreaMed CrossRef
  43. Li H, Zhang Y, Lan X, et al. Halofuginone sensitizes lung cancer organoids to cisplatin via suppressing PI3K/AKT and MAPK signaling pathways. Front Cell Dev Biol 2021;9:773048.
    Pubmed KoreaMed CrossRef
  44. Hu Y, Sui X, Song F, et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nat Commun 2021;12:2581.
    Pubmed KoreaMed CrossRef
  45. Yokota E, Iwai M, Yukawa T, et al. Clinical application of a lung cancer organoid (tumoroid) culture system. NPJ Precis Oncol 2021;5:29.
    Pubmed KoreaMed CrossRef
  46. Oh B, Kim J, Kim N, Jeong Y. Lung cancer organoid system to evaluate the cytotoxicity of natural killer cells. Int J Stem Cells 2024. [Epub] https://doi.org/10.15283/ijsc24021
    CrossRef
  47. Naranjo S, Cabana CM, LaFave LM, et al. Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform. Genes Dev 2022;36:936-49.
    Pubmed KoreaMed CrossRef
  48. Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, et al. Long-term expanding human airway organoids for disease modeling. EMBO J 2019;38:e100300.
    Pubmed KoreaMed CrossRef
  49. Zhang Y, Hu Q, Pei Y, et al. A patient-specific lung cancer assembloid model with heterogeneous tumor microenvironments. Nat Commun 2024;15:3382.
    Pubmed KoreaMed CrossRef
  50. Valančiūtė A, Mathieson L, O'Connor RA, et al. Phototherapeutic induction of immunogenic cell death and CD8+ T cell-granzyme B mediated cytolysis in human lung cancer cells and organoids. Cancers (Basel) 2022;14:4119.
    Pubmed KoreaMed CrossRef
  51. Nikolić MZ, Rawlins EL. Lung organoids and their use to study cell-cell interaction. Curr Pathobiol Rep 2017;5:223-31.
    Pubmed KoreaMed CrossRef
  52. Wu X, Verschut V, Woest ME, et al. Rho-kinase 1/2 inhibition prevents transforming growth factor-β-induced effects on pulmonary remodeling and repair. Front Pharmacol 2021;11:609509.
    Pubmed KoreaMed CrossRef
  53. Keeler SP, Wu K, Zhang Y, et al. A potent MAPK13-14 inhibitor prevents airway inflammation and mucus production. Am J Physiol Lung Cell Mol Physiol 2023;325:L726-40.
    Pubmed KoreaMed CrossRef
  54. Wu K, Zhang Y, Mao D, et al. MAPK13 controls structural remodeling and disease after epithelial injury. bioRxiv [Preprint]. 2024 [cited 2024 Oct 15]. Available from: https://doi.org/10.1101/2024.05.31.596863
    CrossRef
  55. Ciminieri C, Woest ME, Reynaert NL, et al. IL-1β Induces a proinflammatory fibroblast microenvironment that impairs lung progenitors' function. Am J Respir Cell Mol Biol 2023;68:444-55.
    Pubmed KoreaMed CrossRef
  56. Kortekaas RK, Geillinger-Kästle KE, Borghuis T, et al. Interleukin-11 disrupts alveolar epithelial progenitor function. ERJ Open Res 2023;9:00679-2022.
    Pubmed KoreaMed CrossRef
  57. Chen D, Gregory AD, Li X, et al. RIP3-dependent necroptosis contributes to the pathogenesis of chronic obstructive pulmonary disease. JCI Insight 2021;6:e144689.
    Pubmed KoreaMed CrossRef
  58. Wu X, van Dijk EM, Ng-Blichfeldt JP, et al. Mesenchymal WNT-5A/5B signaling represses lung alveolar epithelial progenitors. Cells 2019;8:1147.
    Pubmed KoreaMed CrossRef
  59. Pouwels SD, Hesse L, Wu X, et al. LL-37 and HMGB1 induce alveolar damage and reduce lung tissue regeneration via RAGE. Am J Physiol Lung Cell Mol Physiol 2021;321:L641-52.
    Pubmed KoreaMed CrossRef
  60. Joe YA, Lee MJ, Choi HS. Experimental mouse models and human lung organoid models for studying chronic obstructive pulmonary disease. Biomol Ther (Seoul) 2024;32:685-96.
    Pubmed KoreaMed CrossRef
  61. Song S, van Dijk F, Vasse GF, et al. Inhalable textile microplastic fibers impair airway epithelial differentiation. Am J Respir Crit Care Med 2024;209:427-43.
    Pubmed KoreaMed CrossRef
  62. Oh CK, Murray LA, Molfino NA. Smoking and idiopathic pulmonary fibrosis. Pulm Med 2012;2012:808260.
    Pubmed KoreaMed CrossRef
  63. Suezawa T, Kanagaki S, Moriguchi K, et al. Disease modeling of pulmonary fibrosis using human pluripotent stem cell-derived alveolar organoids. Stem Cell Reports 2021;16:2973-87.
    Pubmed KoreaMed CrossRef
  64. Lee J, Kim JH, Hong SH, Yang SR. Organoid model in idiopathic pulmonary fibrosis. Int J Stem Cells 2021;14:1-8.
    Pubmed KoreaMed CrossRef
  65. Xu Y, Xin W, Yan C, et al. Organoids in lung cancer: a teenager with infinite growth potential. Lung Cancer 2022;172:100-7.
    Pubmed KoreaMed CrossRef
  66. Valdoz JC, Franks NA, Cribbs CG, et al. Soluble ECM promotes organotypic formation in lung alveolar model. Biomaterials 2022;283:121464.
    Pubmed KoreaMed CrossRef
  67. Kang D, Lee Y, Kim W, Lee HR, Jung S. 3D pulmonary fibrosis model for anti-fibrotic drug discovery by inkjet-bioprinting. Biomed Mater 2022;18:015024.
    Pubmed KoreaMed CrossRef
  68. Lee J, Taneja V, Vassallo R. Cigarette smoking and inflammation: cellular and molecular mechanisms. J Dent Res 2012;91:142-9.
    Pubmed KoreaMed CrossRef
  69. Liu W, Zhao Y, Fan J, et al. Smoke and spike: benzo[a]pyrene enhances SARS-CoV-2 infection by boosting NR4A2-induced ACE2 and TMPRSS2 expression. Adv Sci (Weinh) 2023;10:e2300834.
    Pubmed KoreaMed CrossRef
  70. Choi S, Kim EM, Kim SY, et al. Particulate matter exposure exacerbates cellular damage by increasing stress granule formation in respiratory syncytial virus-infected human lung organoids. Environ Pollut 2022;315:120439.
    Pubmed KoreaMed CrossRef
  71. Edwards CE, Tata A, Baric RS. Human lung organoids as a model for respiratory virus replication and countermeasure performance in human hosts. Transl Res 2022;250:36-45.
    Pubmed KoreaMed CrossRef
  72. Chen YW, Huang SX, de Carvalho ALRT, et al. A three-dimensional model of human lung development and disease from pluripotent stem cells. Nat Cell Biol 2017;19:542-9.
    Pubmed KoreaMed CrossRef
  73. Li X, Lin B, Zhang H, et al. Cytotoxicity and mutagenicity of sidestream cigarette smoke particulate matter of different particle sizes. Environ Sci Pollut Res Int 2016;23:2588-94.
    Pubmed KoreaMed CrossRef

PHWR